Trial
NCT01672879
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Liver Fibrosis Due to NASH
Intervention
Placebo
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-27